Abbott Laboratories Stock Forecast, Price & News

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABT shares have increased by 45.1% and is now trading at $113.29.
View which stocks have been most impacted by COVID-19.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Abbott Laboratories stock.
View analyst ratings for Abbott Laboratories or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

538 employees have rated Abbott Laboratories CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Abbott Laboratories' employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Abbott Laboratories.

Abbott Laboratories will be holding an earnings conference call on Wednesday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Wednesday, October, 21st. The healthcare product maker reported $0.98 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.90 by $0.08. The healthcare product maker earned $8.85 billion during the quarter, compared to the consensus estimate of $8.53 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The company's revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.84 earnings per share.
View Abbott Laboratories' earnings history.

Abbott Laboratories declared a quarterly dividend on Friday, December 11th. Shareholders of record on Friday, January 15th will be paid a dividend of $0.45 per share on Tuesday, February 16th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.59%. The ex-dividend date of this dividend is Thursday, January 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.36.
View Abbott Laboratories' dividend history.

Abbott Laboratories pays an annual dividend of $1.80 per share and currently has a dividend yield of 1.62%. Abbott Laboratories has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Abbott Laboratories is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.10% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.
View Abbott Laboratories' dividend history.

16 equities research analysts have issued twelve-month price objectives for Abbott Laboratories' stock. Their forecasts range from $94.00 to $130.00. On average, they anticipate Abbott Laboratories' share price to reach $115.69 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for Abbott Laboratories or view Wall Street analyst' top-rated stocks.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all of ABT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.10%), Gateway Investment Advisers LLC (0.04%), Welch & Forbes LLC (0.04%), Huntington National Bank (0.03%), Gofen & Glossberg LLC IL (0.03%) and Park National Corp OH (0.03%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Hexavest Inc., Gateway Investment Advisers LLC, Rhenman & Partners Asset Management AB, State of Alaska Department of Revenue, Autus Asset Management LLC, Lantz Financial LLC, and Chesley Taft & Associates LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories or view top insider-selling stocks.

ABT stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Tandem Investment Advisors Inc., Journey Advisory Group LLC, Hendley & Co. Inc., IFM Investors Pty Ltd, Bath Savings Trust Co, Louisiana State Employees Retirement System, and Grant GrossMendelsohn LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories or or view top insider-buying stocks.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $113.29.

Abbott Laboratories has a market capitalization of $200.79 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

The official website for Abbott Laboratories is www.abbott.com.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.